Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Sales: 2016-2025

Historic Return on Sales for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -4.26%.

  • Editas Medicine's Return on Sales fell 85.00% to -4.26% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.26%, marking a year-over-year decrease of 85.00%. This contributed to the annual value of -7.34% for FY2024, which is 540.00% down from last year.
  • Per Editas Medicine's latest filing, its Return on Sales stood at -4.26% for Q3 2025, which was up 29.36% from -6.03% recorded in Q2 2025.
  • Editas Medicine's Return on Sales' 5-year high stood at -1.57% during Q1 2021, with a 5-year trough of -11.18% in Q4 2022.
  • Moreover, its 3-year median value for Return on Sales was -6.03% (2025), whereas its average is -5.75%.
  • Per our database at Business Quant, Editas Medicine's Return on Sales plummeted by 771bps in 2021 and then surged by 924bps in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's Return on Sales stood at -7.54% in 2021, then slumped by 365bps to -11.18% in 2022, then skyrocketed by 924bps to -1.94% in 2023, then plummeted by 540bps to -7.34% in 2024, then crashed by 85bps to -4.26% in 2025.
  • Its Return on Sales stands at -4.26% for Q3 2025, versus -6.03% for Q2 2025 and -7.00% for Q1 2025.